title: Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists omega-conotoxin GVIA and omega-conotoxin MVIIA.
abstract: Convection-enhanced delivery (CED) permits the homogeneous distribution of therapeutic agents throughout localized regions of the brain parenchyma without causing tissue damage as occurs with bolus injection. Here, we examined whether CED infusion of the N-type calcium channel antagonists omega-conotoxin GVIA (omega-CTX-G) and omega-conotoxin MVIIA (omega-CTX-M) can attenuate kindling measures in fully amygdala-kindled rats. Rats were implanted with a combination infusion cannula-stimulating electrode assembly into the right basolateral amygdala. Fully kindled animals received infusions of vehicle, omega-CTX-G (0.005, 0.05, and 0.5 nmol), omega-CTX-M (0.05, 0.15, and 0.5 nmol), proteolytically inactivated omega-CTX-M (0.5 nmol), or carbamazepine (500 nmol) into the stimulation site. CED of omega-CTX-G and omega-CTX-M over a 20-min period resulted in a dose-dependent increase in the afterdischarge threshold and a decrease in the afterdischarge duration and behavioral seizure score and duration during a period of 20 min to 1 week after the infusion, indicating an inhibitory effect on the triggering and expression of kindled seizures. The protective effects of omega-conotoxins reached a maximum at 48 h postinfusion, and then they gradually resolved over the next 5 days. In contrast, carbamazepine was active at 20 min but not at 24 h after the infusion, whereas CED of vehicle or inactivated omega-CTX-M had no effect. Except for transient tremor in some rats receiving the highest toxin doses, no adverse effects were observed. These results indicate that local CED of high-molecular-weight presynaptic N-type calcium channel blockers can produce long-lasting inhibition of brain excitability and that they may provide prolonged seizure protection in focal seizure disorders.
authors: Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
authors: Maciej
authors: M
authors: Gasior
authors: Natalie A
authors: NA
authors: White
authors: Michael A
authors: MA
authors: Rogawski
mesh_terms: D000679:Amygdala / Q000187:drug effects*; D000818:Animals; D002121:Calcium Channel Blockers / Q000008:administration & dosage*; D002220:Carbamazepine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007276:Injections, Intraventricular; D007696:Kindling, Neurologic / Q000187:drug effects*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D020866:omega-Conotoxin GVIA / Q000008:administration & dosage* / Q000378:metabolism; D020960:omega-Conotoxins / Q000008:administration & dosage* / Q000378:metabolism
chemical_list: D002121:Calcium Channel Blockers; D020960:omega-Conotoxins; D002220:Carbamazepine; C078452:ziconotide; D020866:omega-Conotoxin GVIA
references: Neurology. 2005 Jun 28;64(12 Suppl 3):S2-11
references: 15994220
references: Neuropharmacology. 1994 Feb;33(2):255-8
references: 8035912
references: Brain Res Brain Res Rev. 2004 Mar;44(2-3):141-53
references: 15003390
references: Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80
references: 8134351
references: Neuropharmacology. 1984 Oct;23(10):1117-23
references: 6521848
references: Science. 1985 Dec 20;230(4732):1338-43
references: 4071055
references: J Mol Biol. 1982 May 5;157(1):105-32
references: 7108955
references: Int J Pept Protein Res. 1995 Sep-Oct;46(3-4):320-5
references: 8537186
references: Eur J Pharmacol. 1989 Dec 19;174(2-3):261-6
references: 2560980
references: J Neurosurg. 2002 Oct;97(4):905-13
references: 12405380
references: Eur J Pharmacol. 1993 Jul 20;238(2-3):383-6
references: 8104812
references: Biochemistry. 1987 Apr 21;26(8):2086-90
references: 2441741
references: Neuron. 1993 Nov;11(5):895-902
references: 7902110
references: Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94
references: 4110397
references: Epilepsia. 2003 Nov;44(11):1425-33
references: 14636351
references: J Neurosci. 1994 Sep;14(9):5613-22
references: 8083757
references: Peptides. 2000 Apr;21(4):491-501
references: 10822104
references: Pain. 1995 Jan;60(1):83-90
references: 7715945
references: Pflugers Arch. 1995 Apr;429(6):873-5
references: 7603842
references: Psychopharmacology (Berl). 1996 Jul;126(1):85-90
references: 8853221
references: J Mol Recognit. 2000 Mar-Apr;13(2):55-70
references: 10822250
references: J Neurosurg. 1995 Jun;82(6):1021-9
references: 7539062
references: J Biol Chem. 2003 May 30;278(22):20171-8
references: 12654924
references: Annu Rev Pharmacol Toxicol. 1995;35:707-34
references: 7598513
references: Neurosci Lett. 1988 Aug 15;91(1):84-8
references: 2845309
references: Neurosurgery. 2003 Feb;52(2):388-93; discussion 393-4
references: 12535369
references: Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):269-79
references: 4110396
references: Curr Opin Oncol. 2000 May;12(3):187-93
references: 10841189
references: Br J Pharmacol. 1991 Jul;103(3):1733-9
references: 1657265
references: Epilepsy Res. 1999 Feb;33(2-3):159-67
references: 10094427
references: Eur J Neurosci. 1991;3(10):992-1000
references: 12106257
references: Brain Res Bull. 1981 Dec;7(6):629-33
references: 7326579
references: Trends Neurosci. 1997 May;20(5):204-12
references: 9141196
references: J Neurosurg. 1999 Feb;90(2):315-20
references: 9950503
references: J Neurosurg. 1999 Feb;90(2):321-31
references: 9950504
references: J Biol Chem. 1986 May 15;261(14):6230-3
references: 2939072
references: Epilepsia. 1976 Jun;17(2):197-206
references: 947748
references: Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5058-62
references: 1317580
references: Biochemistry. 1995 Jun 27;34(25):8076-81
references: 7794920